The Highwire with Del Bigtree - THE GREAT DECLINE: PFIZER SHOT EFFICACY IN YOUTH WANES IN DAYS

Episode Date: August 28, 2022

The great decline from 100% to ZERO efficacy has begun for adolescent Covid shots. After initially proclaiming perfect efficacy for the experimental mRNA vaccine technology, new research shows the efficacy of Pfizer’s two-dose shot drops after just 27 days.#TheGreatDecline #VaccinatingYouth #Efficacy #Pfizer #InformedConsentBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

When you see headlines that look like this, this is from last year, Pfizer says COVID-19 vaccine shows 100% efficacy in adolescence. There's your first question. When Pfizer says and 100% efficacy, those should send alarm bells and say, wait a minute, I remember this segment about the science. I maybe should question this. And even the FDA, listen to this. This was a press release on the back of that when they authorized their Pfizer shot, their COVID-19 Pfizer shot for emergency use in adolescents. and part of the data they use, the efficacy data to show this thing is really effective at that time, they say this, the immune response. That's basically just the antibodies generated, just an immune

response. We generated some antibodies to the vaccine in 190 participants 12 through 15 years of age was compared to the immune response, some other antibodies, of 170 participants 16 through 25 years of age. So they compared them. They just said, this looks like that. Therefore, let's put it in tens of millions of people, kids. In this analysis, the immune response of adolescents was not inferior to, at least as good as, the antibody immune response of the older participants. And for people that are joining us just brand new here, this is something I know when we hear antibodies, we think, oh, it means we're immune. It truly does not. There's all sorts of different antibodies. There's neutralizing antibodies. There's binding antibodies. But in this,

there's never been proof that antibodies deliver full protection or what level of protection. So when they're saying you're getting the same amount of antibodies as this other group that was in a trial that we cut short and never ran long enough to see anything of actual value, they're just doing comparative or what they call immunobringing, right? This immune bridging thing was, well, it looked like the same antibodies as the other group. And we lied until the world it was effective for them. So let's lie until the world's effective for the children comparing one crappy group to the next is how our science is being done. And when we reported that at the time, the adult vaccinations, their efficacy was waning, waning, waning, and people are saying, right, you're going to give this to kids. Isn't the same thing going to happen? No, no, 100% says Pfizer. Let's check it on Pfizer shot. How is it doing in adolescents now? Here's the headline. Study, Pfizer COVID vaccine efficacy wanes 27 days after dose 2 in teens.

Wow. And there you have it. And this is the study here. This was published this month in the Lancet. If anybody wants to actually look at the data, they looked at kids in Brazil. in Scotland from 27 days after the second dose they found waning. It was reduced in Brazil to 5.9% by 98 days or more that was during the Omicrom period. So, you know, boosters, boosters and boosters. Well, what are you going to do? If it's every 27 days, we're going to do a booster every single month. Is this the world you all want to live in? This is good science. Let's just keep boosting you and boosting and forget what that's doing your immune system and all the reports we've done on immune exhaustion, and all the other problems that come from being vaccinated that often. And let me tell you, no one's immune to this effect.

Even Pfizer's own CEO, Albert Borla, has become a victim of his shot's lack of success, lack of efficacy. He took to Twitter. This was in April 2021. He was a really happy guy then. He said, excited to share that updated analysis from our phase three study with Bioentech also showed that our COVID-19 vaccine was 100. percent effective in preventing COVID-19 cases in South Africa. A hundred percent, he says, with happiness.

Let's check on him, August 15. 30 billion dollars in sales later. This is what he has to say. Okay. Really big pockets for him. So this is what he had to say. He took to Twitter. I would like to let you know that I have tested positive for COVID-19. I'm thankful to have received four doses of the Pfizer-Biointech vaccine. And I'm feeling well while experiencing very mild symptoms. I am isolating and have started a course of Paxlovid. Oh, I love that. A drug, by the way, that is only if you're in severe risk of having a bad outcome. So obviously the guy that got four of these shots is not actually convinced that it's going to reduce his symptoms enough.

He's on a drug that's going to suffer bouncebacks and all sorts of other problems. You know, these guys really would do themselves a favor if they would just, and they probably are. I'll bet you behind closed doors, he's taking hydroxychloroquine, ivermectin, and is ithromized. If he's not, he's an absolute moron. Right. And so where are we going from here? Let's pull out the crystal ball. And the UK has become the first country to approve a Amacron variant booster.

So up until now, we have been using the original strain to be fighting all these variants. So the UK approve Omicron-specific booster shots. They're coming to the U.S. soon. And this is the headlines here in the United States. Biden administration plans to offer updated booster shots in September. Now, the UK is the Wuhan strain and the Bucon. B.A.1 sub-variant. That's the original, the earliest Omicron strain. The FDA is pushing the Moderna and the vaccine makers to put in BA4 and BA5. That's the current variant. But, you know,

if they're not out by fall, these variants seem to move fairly quickly. So that's going to be a question too. But what do we do know about the vaccines? You know, we do know they produce these antibodies. People keep saying they produce antibodies. What does that actually translate? to in the real world. Is there any correlation of protection between producing these antibodies and let's say severe disease, hospitalization, all this stuff that they're selling us on the vaccine? Well, let's listen to this is the Pfizer's vice president of viral vaccine research and development. And question by this man, Dr. Offer Levy. He's a director of precision vaccine program at Boston Children's Hospital. He's also a professor of pediatrics at Harvard Medical School. This was a recent

Verpak committee and he had some questions for Pfizer's vice president. Take a listen. All right. Obviously in a difficult situation, try quickly and it's hard to generate sufficient information to know exactly what the right path is. So regarding your murine data, you showed the of neutralizing antibodies against BA 4 and 5. We're able to challenge the mice to show that you had protect the mice against clinical disease. Do you have an opinion as to what your correlative protection is in humans? And thirdly, have you made use of any human in vitro models to assess your vaccines?

Thank you. So to answer, thank you, Dr. Lieber, for the question. To answer the first, no, we have not challenged the mice. These data just became available this morning. So we wanted to share the late breaking of all of the totality of evidence that we have on variant-modified vaccines. So these are to show the breadth of neutralization, whether you're talking about a BA1 modified or a BA4 modified vaccine compared to prototype. And then can you repeat the second question?

I mean, obviously you have a lot of data now. What is your correlative protection is? Everybody's measuring anybody's. They're probably relevant. But as we know, it's a long question. We need a quick answer. Yes. I would say there is no established correlate of protection.

Wow, I mean this and this is it. Is this what we're going to be rehashing inside the CDC and the FDA? Maybe it's not such a good idea to be making recommendations based on zero correlates of protection. No proof the product actually works. Oh, and by the way, let's make sure we rush the one question that is being asked that actually makes some sense to the future health of millions and millions of people.